2019
DOI: 10.3233/blc-199009
|View full text |Cite
|
Sign up to set email alerts
|

Modeling Tumor Heterogeneity in Bladder Cancer: The Current State of the Field and Future Needs

Abstract: BACKGROUND: Tumor heterogeneity has been recognized in many cancer types for decades. However, the significance of tumor heterogeneity on disease course and clinical outcome in bladder cancer is of more recent interest to researchers and clinicians. This is especially true as morphologic and molecular heterogeneity has the potential to confound accurate diagnosis, efficient prognostication, and subsequent clinical management. While this is true, it is not always clear what laboratory models are available or su… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 60 publications
(71 reference statements)
0
1
0
Order By: Relevance
“…The majority of BLCa preclinical research has been performed on a small number of cell lines which poorly recapitulate the characteristics of human tumor. Mouse models of BLCa, including genetically engineered, carcinogen-induced and patient-derived xenograft models, have been described but are not suitable for the study of molecular heterogeneity (33,49,50). Over the last few years, personalized medicine approaches have been tested for their feasibility and clinical effectiveness across a variety of cancer types.…”
Section: Discussionmentioning
confidence: 99%
“…The majority of BLCa preclinical research has been performed on a small number of cell lines which poorly recapitulate the characteristics of human tumor. Mouse models of BLCa, including genetically engineered, carcinogen-induced and patient-derived xenograft models, have been described but are not suitable for the study of molecular heterogeneity (33,49,50). Over the last few years, personalized medicine approaches have been tested for their feasibility and clinical effectiveness across a variety of cancer types.…”
Section: Discussionmentioning
confidence: 99%